Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.

Eli Lilly (LLY) on Monday announced an agreement to acquire Kelonia Therapeutics, a privately held cancer drug developer, in a deal worth up to $7B in cash, confirming a prior report from The Wall ...

Eli Lilly researchers at work. Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, the companies said today, in a deal that would bolster the buyer’s oncology pipeline with an early ...

By Siddhi Mahatole April 20 (Reuters) - U.S. drugmaker Eli Lilly will buy privately held biotech firm Kelonia Therapeutics for up to $7 billion, gaining access to experimental cancer treatments as it ...

April 19 (Reuters) - U.S. drugmaker Eli Lilly (LLY) is in advanced talks to acquire biotech firm Kelonia ‌Therapeutics for more than $2 billion, the Wall ‌Street Journal reported on Sunday. A deal ...

Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, the companies announced Monday. The acquisition will grant ...

Eli Lilly (LLY) is in advanced negotiations to acquire Kelonia Therapeutics in a transaction valued at more than $2 billion, The Wall Street Journal reported Sunday, citing people familiar with the ...

April 20 (Reuters) - U.S. drugmaker Eli Lilly ⁠will ⁠buy privately held biotech firm ⁠Kelonia Therapeutics for up to $7 billion, gaining access to experimental cancer treatments as it bolsters its ...

Add Yahoo as a preferred source to see more of our stories on Google. April 19 (Reuters) - U.S. drugmaker Eli Lilly (LLY) is in advanced talks to acquire biotech firm Kelonia ‌Therapeutics for more ...

U.S. drugmaker Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion, The Wall Street Journal reported on Sunday. A deal could be reached as soon as ...